FDA-cleared profile

Vitrea CT Transcatheter Aortic Valve Replacement (TAVR) Planning

Canon Medical Informatics, Inc. · CT/CTA · FDA-cleared (510(k))

Authorized purpose: Assist assessment and pre-operative planning and post-operative evaluation of transcatheter aortic valve replacement procedures.

Clinical role
AI-assisted segmentation, landmark detection, contouring, measurement, visualization, reporting, and TAVR approach-planning support; all initialized outputs require user review/editing before reporting.
Images and patients
CT/CTA · Aortic valve/root, LVOT and ventricles, coronary ostia, cardiac structures, and iliac/femoral/abdominal aortic access vessels
Key limitation
Keep in mind: Validation excluded severe motion artifacts and poor-contrast or non-diagnostic phases. Automatically initialized outputs must be reviewed, edited as needed, and manually approved before reporting. The packet's quantitative validation is retrospective and tied to the tested CT protocols and scanners.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: Assist assessment and pre-operative planning and post-operative evaluation of transcatheter aortic valve replacement procedures.
  • Which images or clinical context are in scope?Modality: CT/CTA Anatomy or clinical context: Aortic valve/root, LVOT and ventricles, coronary ostia, cardiac structures, and iliac/femoral/abdominal aortic access vessels Input: Contrast-enhanced CTA DICOM images for TAVR candidates, with packet validation using slice thickness <=1.0 mm, 100-120 kVp, systolic 20-30% and diastolic approximately 80% phases, and Canon, Siemens, GE, and Philips scanners.
  • Who uses it?Intended users: Cardiologists, radiologists, and clinical specialists.
  • What does the software produce?Output: User-editable automatic initialization of selected aortic-root visualizations, landmarks, and measurements using the TAVR Planning Assist feature; the broader software provides 3D segmentation and visualization of heart structures/vessels, calcium, leaflets, and vascular access; C-arm angles, centerlines, tortuosity, delivery-path planning, and reports with approach-planning/device-sizing measurements.
  • What is its most important limitation?Key limitation: Validation excluded severe motion artifacts and poor-contrast or non-diagnostic phases. Automatically initialized outputs must be reviewed, edited as needed, and manually approved before reporting. The packet's quantitative validation is retrospective and tied to the tested CT protocols and scanners.

Clinical takeaway. Clinical role: Assist assessment and pre-operative planning and post-operative evaluation of transcatheter aortic valve replacement procedures.

Evidence takeaway. Evidence from the reviewed source record: FDA packet: 89 independent retrospective TAVR CT cases, with ground truth from two independent board-certified cardiac CT readers. Measurement agreement used ICC and Bland-Altman analyses; optional leaflet coloring had over 93% of cases rated Good or Excellent. The validation included scanner, slice-thickness, kVp, reconstruction, calcification, age, sex, and geographic subgroups.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
Assist assessment and pre-operative planning and post-operative evaluation of transcatheter aortic valve replacement procedures.
  • Exact FDA submission
  • Checked 2026-09-08
Workflow role
AI-assisted segmentation, landmark detection, contouring, measurement, visualization, reporting, and TAVR approach-planning support; all initialized outputs require user review/editing before reporting.
  • Exact FDA submission
  • Checked 2026-09-08
Required input
Contrast-enhanced CTA DICOM images for TAVR candidates, with packet validation using slice thickness <=1.0 mm, 100-120 kVp, systolic 20-30% and diastolic approximately 80% phases, and Canon, Siemens, GE, and Philips scanners.
  • Exact FDA submission
  • Checked 2026-09-08
Output and clinician action
User-editable automatic initialization of selected aortic-root visualizations, landmarks, and measurements using the TAVR Planning Assist feature; the broader software provides 3D segmentation and visualization of heart structures/vessels, calcium, leaflets, and vascular access; C-arm angles, centerlines, tortuosity, delivery-path planning, and reports with approach-planning/device-sizing measurements.
  • Exact FDA submission
  • Checked 2026-09-08
Care setting
Clinical setting for patients identified as candidates for TAVR; the packet also describes use on a radiology workstation and pre-/post-operative planning.
  • Exact FDA submission
  • Checked 2026-09-08
Intended users
Cardiologists, radiologists, and clinical specialists.
  • Exact FDA submission
  • Checked 2026-09-08
Limitations
Validation excluded severe motion artifacts and poor-contrast or non-diagnostic phases. Automatically initialized outputs must be reviewed, edited as needed, and manually approved before reporting. The packet's quantitative validation is retrospective and tied to the tested CT protocols and scanners.
  • Exact FDA submission
  • Checked 2026-09-08
Evidence summary
FDA packet: 89 independent retrospective TAVR CT cases, with ground truth from two independent board-certified cardiac CT readers. Measurement agreement used ICC and Bland-Altman analyses; optional leaflet coloring had over 93% of cases rated Good or Excellent. The validation included scanner, slice-thickness, kVp, reconstruction, calcification, age, sex, and geographic subgroups.
  • Exact FDA submission
  • Checked 2026-09-08

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
FDA packet: 89 independent retrospective TAVR CT cases, with ground truth from two independent board-certified cardiac CT readers. Measurement agreement used ICC and Bland-Altman analyses; optional leaflet coloring had over 93% of cases rated Good or Excellent. The validation included scanner, slice-thickness, kVp, reconstruction, calcification, age, sex, and geographic subgroups.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-08
Reported sensitivity
Research pending
  • Needs research
  • Exact FDA submission
  • Checked 2026-08-31

This field has not been curated yet.

Reported specificity
Research pending
  • Needs research
  • Exact FDA submission
  • Checked 2026-08-31

This field has not been curated yet.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

Vitrea CT Transcatheter Aortic Valve Replacement (TAVR) Planning regulatory performance study summary

  • DesignStand-Alone Performance
  • PopulationAdult
  • Scopeexact submission
  • Tested versionExact product version not reported; regulatory study summarized for FDA submission K260324
  • Samplen=89
  • IndependenceIndependence not established

K260324

ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K260324. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-08
Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not verified: Pricing information is recorded but not verified against a resolving source.

Reimbursement

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: Contrast-enhanced CTA DICOM images for TAVR candidates, with packet validation using slice thickness <=1.0 mm, 100-120 kVp, systolic 20-30% and diastolic approximately 80% phases, and Canon, Siemens, GE, and Philips scanners.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-08 · FDA K260324: Vitrea CT Transcatheter Aortic Valve Replacement (TAVR) Planning

  2. Routing

    Source context, not route validation: Runs on the Vitrea platform, processes CTA DICOM patient images, and can export results to DICOM-capable image-management, archival, or reporting systems, including DICOM Structured Report when licensed. The packet describes a radiology-workstation environment.

    Scope: Exact FDA submission.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-08 · FDA K260324: Vitrea CT Transcatheter Aortic Valve Replacement (TAVR) Planning

  3. AI processing

    Unresolved route: Not established for the exact route.

    Scope: Exact FDA submission. The reviewed sources do not establish the current exact-release hosting topology, data flow, region, tenancy, or disaster-recovery configuration.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-08 ·

  4. Returned objects

    Source context, not route validation: User-editable automatic initialization of selected aortic-root visualizations, landmarks, and measurements using the TAVR Planning Assist feature; the broader software provides 3D segmentation and visualization of heart structures/vessels, calcium, leaflets, and vascular access; C-arm angles, centerlines, tortuosity, delivery-path planning, and reports with approach-planning/device-sizing measurements.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-08 · FDA K260324: Vitrea CT Transcatheter Aortic Valve Replacement (TAVR) Planning

  5. Viewer/worklist/report

    Unresolved route: User-editable automatic initialization of selected aortic-root visualizations, landmarks, and measurements using the TAVR Planning Assist feature; the broader software provides 3D segmentation and visualization of heart structures/vessels, calcium, leaflets, and vascular access; C-arm angles, centerlines, tortuosity, delivery-path planning, and reports with approach-planning/device-sizing measurements.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-08 · FDA K260324: Vitrea CT Transcatheter Aortic Valve Replacement (TAVR) Planning

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Integration
Runs on the Vitrea platform, processes CTA DICOM patient images, and can export results to DICOM-capable image-management, archival, or reporting systems, including DICOM Structured Report when licensed. The packet describes a radiology-workstation environment.
  • Exact FDA submission
  • Checked 2026-09-08
Security
Canon Medical Informatics publishes an MDS2 (Manufacturer Disclosure Statement for Medical Device Security, VLC-11241 Rev A, 2024-04-12) for the Vitrea Advanced Visualization platform, which hosts this application: a coordinated vulnerability disclosure program, H-ISAC information sharing via parent Canon, ePHI stored locally on facility equipment (not designed for archival; removable at facility discretion), and DICOM V3.0 exchange over the facility TCP/IP network.
  • Product family
  • Checked 2026-10-27

Vendor statement, not an attestation. The MDS2 names the Vitrea Advanced Visualization platform, not this specific application release; Canon Medical Informatics' Vitrea neuro/cardiac pages document CT Transcatheter Aortic Valve Replacement as an application within that platform (applicant Vital Images, Inc. is Canon Medical Informatics' predecessor name for the Vitrea line). Exact-release scope is not established.

Input or output interoperability

DICOM is explicitly referenced in the described input, output, or workflow.

exact submission · checked 2026-09-01

The model card does not establish every supported DICOM object, transfer method, or local interface.

ACR exact-submission catalog context

ACR AI Central provides an exact-submission model card for Vitrea CT Transcatheter Aortic Valve Replacement (TAVR) Planning; FDA labeling remains controlling for clinical use, limitations, and performance.

exact submission · checked 2026-09-08
Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K260324
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
CT/CTA
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-08
Anatomy
Aortic valve/root, LVOT and ventricles, coronary ostia, cardiac structures, and iliac/femoral/abdominal aortic access vessels
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-08
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2026-05-22
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Exact FDA record reviewedStatus
2026-09-20Last searched
22Fields reviewed
9Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, acr ai central product, fda decision summary, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not verified - checked 2026-09-08 - Exact FDA submission

    No public price or quote for the exact K260324 configuration was established in this review.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not publicly available - checked 2026-09-08 - Exact FDA submission

    No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.

  • Deployment: Not verified - checked 2026-09-08 - Exact FDA submission

    The reviewed sources do not establish the current exact-release hosting topology, data flow, region, tenancy, or disaster-recovery configuration.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Installation timeline: Not yet reviewed
  • Training: Not verified - checked 2026-09-08 - Exact FDA submission

    Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.

  • Monitoring: Not verified - checked 2026-09-08 - Exact FDA submission

    Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.

9 sources - 3 history items

Source ledger

  1. FDA K260324: Vitrea CT Transcatheter Aortic Valve Replacement (TAVR) Planning

    U.S. Food and Drug Administration - Published 2026-05-22 - Accessed 2026-09-08

    Scope: identity, clinicalUse, modality, anatomy, workflow, evidence, implementation

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. Vitrea CT Transcatheter Aortic Valve Replacement (TAVR) Planning model card (K260324)

    American College of Radiology - Published 2026-08-17 - Accessed 2026-09-01

    Scope: intendedUsers, careSetting, output, limitations, evidenceSummary, integration, anatomy, evidenceStudies, implementationCapabilities

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. openFDA exact recall query for K260324

    U.S. Food and Drug Administration - Accessed 2026-09-08

    Scope: postmarketSafety

  8. Manufacturer Disclosure Statement for Medical Device Security (MDS2): Vitrea Advanced Visualization (VLC-11241 Rev A)

    Canon Medical Informatics, Inc. - Published 2024-04-12 - Accessed 2026-10-27

    Scope: security

  9. Vitrea Advanced Visualization: Neuro (CT Brain Perfusion 2D/4D)

    Canon Medical Informatics, Inc. - Accessed 2026-10-27

    Scope: security

Research history

  1. K260324 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    fda record reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K253786

syngo.CT Coronary Cockpit

Siemens Medical Solutions USA, Inc.

Authorized purpose: An extension for syngo.via that assists trained physicians with automated and semi-automated analysis, visualization and reporting of cardiac CT angiography volume datasets for coronary-lesion evaluation, documentation, follow-up and treatment planning.

Modality
CT/CTA
Anatomy
Heart/Cardiovascular
Decision
2026-06-25
FDA-cleared K253596

Aquilion ONE (TSX-308A/TSX-306A) V2.0

Canon Medical Systems Corporation

Authorized purpose: Canon Aquilion ONE V2.0 acquires and processes whole-body CT volumes, including head, chest, abdomen, pelvis, cardiac, extremity, inner-ear, and multi-energy examinations with the labeled reconstruction functions.

Modality
CT/CTA
Anatomy
Whole body; head; chest; abdomen; pelvis; heart; extremities; and inner ear
Decision
2026-05-20
FDA-cleared K254120

SubtleHD-CT (1.x)

Subtle Medical, Inc.

Authorized purpose: Process and enhance CT images from any CT scanner manufacturer or model as an adjunct to the original reconstructed image.

Modality
CT/CTA
Anatomy
Multiple CT anatomies: abdomen, C-spine, cardiac, chest, chest-abdomen-pelvis, head, head/neck, L-spine, lower extremity, MSK, T-spine, and upper extremity.
Decision
2026-05-15

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history